Combinational chemotherapy of L1210 and L1210/ARA-C leukemia with 5-AZA-2'-deoxycytidine and beta-2'-deoxythioguanosine.

Abstract

The in vitro and in vivo antineoplastic activity of 5-AZA-2'-deoxycytidine (5-AZA-CdR) and beta-2'-deoxythioguanosine (TGdR) on L1210 and L1210/ARA-C (resistant to cytosine arabinoside) leukemic cells was investigated. 5-AZA-CdR was a very potent cytotoxic agent against the L1210 leukemia cells. This analogue was inactive against L1210/ARA-C leukemic cells because these cells lack deoxycytidine kinase, the enzyme that converts 5-AZA-CdR to its active nucleotide form. TGdR was a potent cytotoxic agent to both L1210 and L1210/ARA-C leukemic cells. In mice which were injected simultaneously with both L1210 and L1210/ARA-C leukemic cells, the drug combination of 5-AZA-CdR plus TGdR had a very potent antineoplastic activity and produced long-term survivors. Either agent alone did not produce any long-term survivors in the mice with L1210 and L1210/ARA-C leukemia. This experimental model indicates that 5-AZA-CdR plus TGdR is an interesting drug combination for the treatment of leukemia with drug-resistant cells.

• Authors: R L Momparler, L F Momparler, J Samson
• Journal: International journal of cancer (Int J Cancer) Vol. 30 Issue 3 Pg. 361-64 (Sep 15 1982) ISSN: 0020-7136 [Print] United States
• PMID: 6182115 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antineoplastic Agents
• Thionucleosides
• Decitabine
• beta-2'-deoxythioguanosine
• Deoxyguanosine
• Azacitidine

Topics

• Animals
• Antineoplastic Agents (therapeutic use)
• Azacitidine (analogs & derivatives, therapeutic use)
• Decitabine
• Deoxyguanosine (analogs & derivatives, therapeutic use)
• Drug Evaluation
• Drug Therapy, Combination
• Leukemia L1210 (drug therapy)
• Male
• Mice
• Thionucleosides (therapeutic use)